Infant Bacterial Therapeutics
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Patent for Infant Bacterial Therapeutics has been approved in the USA
Infant Bacterial Therapeutics AB (IBT) announces today that it has been granted a Notice of Allowance from the US Patent and Trademark Office (USPTO), meaning that IBT’s patent application has been approved. The patent pertains to the drug candidate IBP-9414, which has been developed by IBT for the prevention of Necrotizing Enterocolitis (NEC) and to improve the nutritional intake and development of premature infants.
The invention encompasses a unique method of activating freeze-dried bacteria. The patent reinforces the existing intellectual property protection for IBT’s drug candidate IBP-9414. IBT has been granted orphan drug status in both the USA and the EU. Furthermore, IBP-9414 is a biologic medicine which further strengthens protection through data exclusivity in the USA and EU.
The plan is to launch IBP-9414 on the US market as soon as market authorization is obtained. The phase III clinical study was completed in July 2024, and the study results are expected this quarter.
CEO Staffan Strömberg comments, “The intellectual property protection for IBP-9414 was already strong before this US patent was approved, as the project had already been granted Orphan Drug Status and is a biologic. The US market is the largest and most important. Being able to strengthen IP protection and additionally extend its duration is great news.”
| Datum | 2024-08-15, kl 16:44 |
| Källa | MFN |